Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Yan-zhi Chen; Xiao-bing Feng; Zhan-dong Li; Wen-xian Zheng; Hong Sun; Ping-ping Li

doi:10.1007/s11655-014-1770-6

Your Location：

Home >

Browse articles >

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Updated：2021-08-27

- Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine
- Chinese Journal of Integrative Medicine Vol. 20, Issue 3, Pages: 179-183(2014)
- Affiliations：
  
  Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute,Beijing,China
- Author bio：
- Funds：
  
  Supported by the Fund for Scientific and Technologic Projects from Beijing Administration of Traditional Chinese Medicine (No. 2004 Jing Zhong Zhong IV15)
- DOI：10.1007/s11655-014-1770-6
  CLC：
- Published：2014，
  
  Published Online：4 March 2014，
Scan for full text
Chen, Yz., Feng, Xb., Li, Zd. et al. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine., Chin. J. Integr. Med. 20, 179–183 (2014). https://doi.org/10.1007/s11655-014-1770-6

Yan-zhi Chen, Xiao-bing Feng, Zhan-dong Li, et al. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine. [J]. Chinese Journal of Integrative Medicine 20(3):179-183(2014)
Chen, Yz., Feng, Xb., Li, Zd. et al. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine., Chin. J. Integr. Med. 20, 179–183 (2014). https://doi.org/10.1007/s11655-014-1770-6 DOI：

Yan-zhi Chen, Xiao-bing Feng, Zhan-dong Li, et al. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine. [J]. Chinese Journal of Integrative Medicine 20(3):179-183(2014) DOI： 10.1007/s11655-014-1770-6.

摘要

To investigate the prognostic influence on long-term overall survival (OS) from treatment with Chinese medicine (CM) and chemotherapy or targeted therapy in advanced non-small-cell lung cancer (NSCLC) patients. The clinical data of 206 advanced NSCLC patients who were treated with CM and Western medicine in Beijing Cancer Hospital from April 1999 to July 2013 were retrospectively analyzed. Long-term survivors were defined as OS ⩾ 3 years after treatment with CM and chemotherapy. Twenty-eight patients had OS ⩾ 3 years

178 had OS < 3 years

and all clinical data were statistically analyzed with the Cox model. Variables were gender

age

smoking status

performance status (PS) score

pathological type

clinical stage

first-line chemotherapy

targeted therapy

and use of CM. Univariate survival analysis was performed using the Kaplan-Meier method and log-rank sequential inspection. Multivariate survival analysis was used to analyze the meaningful factors of univariate survival analysis with the Cox model. The survival rate of patients with OS ⩾ 3 years was 13.6% (28/206). Cox multivariate regression analysis showed that PS score

clinical stage

disease control rate to first-line chemotherapy

and use of CM were independent factors of longterm OS (all <0.05). However

gender

age

smoking

and use of epidermal growth factor receptor tyrosinekinase inhibitor were not significant (P>0.05). PS score

clinical stage

disease control rate to firstline chemotherapy

and use of CM are probably independent prognostic factors for long-term OS in patients with advanced NSCLC.

Abstract

178 had OS < 3 years

and all clinical data were statistically analyzed with the Cox model. Variables were gender

age

smoking status

performance status (PS) score

pathological type

clinical stage

first-line chemotherapy

targeted therapy

clinical stage

disease control rate to first-line chemotherapy

and use of CM were independent factors of longterm OS (all <0.05). However

gender

age

smoking

and use of epidermal growth factor receptor tyrosinekinase inhibitor were not significant (P>0.05). PS score

clinical stage

disease control rate to firstline chemotherapy

and use of CM are probably independent prognostic factors for long-term OS in patients with advanced NSCLC.

关键词

non-small cell lung cancerlong-term overall survivalprognosisChinese Medicine

Keywords

non-small cell lung cancerlong-term overall survivalprognosisChinese Medicine

references

Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Caner J Clin 2005;55:74–108.

Govindan R, Page N, Morgensztern D, Read W, Tieney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveilance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539–4544.

Sequist LV, Martins RG, Spigel D, Steven MG, Alexander S, Pasia J, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442–2449.

Frances AS, Rodrigues P, Tudor C, Eng Huat Tan, Vera H, Semitra T, et al. Erlotinib in preciously treated non-smallcell lung cancer. N Engl J Med 2005;353:123–132.

Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32:1135–1141.

Ye B, Wang LH, Liu XY. Explaine of the revised versin of lung cancer TNM staging standard by International Association of Lung Cancer. Chin J Med 2008;4:21–23.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216.

Paesmans M, Sculier JP, Libert G. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995;13:1221–1230.

Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–2550.

Ciuleanu T, Brodowicz T, Zielinki C, Kim JH, Kizakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432–1440.

Lin LP, Xiang XJ, Huang H, Zhao HY, Zhang Y. Analysis of the relationship between the response after the firstline chemotherapy and the survival in the advanced non-small cell lung cancer. Chin J Lung Cancer (Chin) 2008;11:333–337.

Wu MN, Wang YY, An TT, Zhao J, Yang L. Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer. Chin J Lung Cancer (Chin) 2011;14:245–250.

Chen YZ, Li ZD, Gao F, Zhang Y, Li PP. Effects of combined Chinese drugs and chemotherapy in treating advanced nonsmall cell lung cancer. Chin J Integr Med 2009;15:415–419.

Chen YZ, Di LJ, Zhang SL, Chen MS. Sun H, Gao F. The randomized, multicenter, controlled clinic trail for treating advanced non-small cell lung cancer with combined traditional Chinese medicine and vinorelbine (Navelbine, NVB) plus cisplatin (DDP) chemotherapy. Chin J Lung Cancer (Chin) 2008;11:441–444.

Chen YZ, Li ZD, Zhou N, Sun H, Li PP. Longer overall survival in a patient with advanced non-small cell lung cancer treated with Chinese medicine and chemotherapy. Chin J Integr Med 2012;18:626–628.

FULL TEXT LINK

More>

Views

691

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma

Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses

Related Author

No data

Related Institution

Department of Oncology, Fuzhou General Hospital, Nanjing Military Command

Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine

Department of Integrative Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Etiology, Peking University Cancer Hospital and Institute

School of Basic Medical Science, Shandong University of Traditional Chinese Medicine

Zhong-Shan-Men Inpatient Department, National Clinical Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰